They used molecular biology techniques to knock down CD24 expression in drug-resistant cells, and the cells were sensitive to sorafenib treatment, indicating that CD24 had a unique role in the phenomenon of DR in liver cancer cells (Lu et al., 2018). This evidence concerns the gene CD24 and liver cancer.